🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Alpa Laboratories Limited ALPA NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.alpalabs.in
Company Profile ↓
₹51.46
-46.28% 1Y
Mkt Cap₹108.27 Cr
P/E30.63
P/B0.64
52W High₹99.47
52W Low₹46.46
Book Value₹88.53
EPS (TTM)₹1.68

Company Overview

Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It offers ethical, generic, and over the counter medicines. The company provides tablets, capsules, injections, syrups, ointments, creams, eye drops, and other dosage forms for human and veterinary healthcare, as well as aquaculture products, including probiotics, deodorizer, minerals, feed supplements, and disinfectant. The company was founded in 1967 and is based in Indore, India.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 30.6, below the sector median of 35.9.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹105.81 Cr (-5.9% YoY); net profit ₹15.01 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +25.2%, earnings -91.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 4.6%, profit CAGR 6.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:4.62%
1 Year:25.20%

Compounded Profit Growth

5 Years:6.06%
1 Year:-91.20%

Stock Price Performance

1 Year:-46.28%
6 Months:-25.89%
3 Months:-22.76%
1 Month:-13.69%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 9% of range
₹46.46 ₹99.47
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)25.69 · Oversold
Price Performance
1M-13.69%
3M-22.76%
6M-25.89%
1Y-46.28%
Valuation vs Sector

P/E of 30.63 is below the sector median of 35.90 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Trading 48.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
30.63
Industry PE
35.90
Forward P/E
9.73
PEG Ratio
-
Book Value
₹88.53
Price to Book
0.64
P/S
1.08
EV/EBITDA
17.55
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
4.62%
Profit 5Y
6.06%
Revenue (YoY)
25.20%
Earnings (YoY)
-91.20%

Profitability & Returns

ROCE
8.94%
ROE
8.06%
ROA
6.20%
Profit Margin
3.82%
Op Margin
-19.54%
Gross Margin
25.54%
EPS (Latest Qtr)
₹0.24
EPS (TTM)
₹1.68

Balance Sheet & Liquidity

Debt/Equity
1.35
Quick Ratio
3.76
Current Ratio
4.01
Debt
₹2.51 Cr
Total Assets
₹242.14 Cr
Current Assets
₹210.90 Cr
Working Capital
₹158.37 Cr

Ownership

Promoter Holding
57.29%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹108.27 Cr
Total Revenue (TTM)
₹110.63 Cr
EBITDA
₹-1.29 Cr
Free Cash Flow
₹6.00 Cr
Operating Cash Flow
₹9.95 Cr
Shares Outstanding
₹2.10 Cr
Gross Margin
25.54%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALPA Alpa Laboratories Limited NSEPHARMA 51.46 30.63 ₹108.27 Cr 0.00% 8.94% 8.06% 4.62% 6.06%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 29.16 Cr25.43 Cr32.39 Cr27.31 Cr23.61 Cr21.44 Cr24.94 Cr26.15 Cr39.92 Cr19.11 Cr26.26 Cr29.05 Cr31.40 Cr
Cost of Revenue --------29.16 Cr12.69 Cr21.43 Cr21.57 Cr18.62 Cr
Gross Profit --------10.76 Cr6.42 Cr4.83 Cr7.47 Cr12.78 Cr
Operating Expenses 19.94 Cr26.57 Cr29.04 Cr24.88 Cr20.10 Cr20.91 Cr21.62 Cr25.41 Cr11.14 Cr6.55 Cr7.74 Cr6.61 Cr9.40 Cr
Operating Income 8.69 Cr-1.42 Cr2.86 Cr1.77 Cr2.99 Cr-1.00 L2.79 Cr19.00 L-38.54 L-12.93 L-2.91 Cr86.33 L3.38 Cr
EBITDA 9.22 Cr-1.14 Cr3.35 Cr2.43 Cr3.51 Cr53.00 L3.32 Cr74.00 L2.67 Cr12.37 Cr81.83 L2.42 Cr3.44 Cr
Interest Expense 4.00 L2.00 L2.00 L2.00 L29.00 L5.00 L5.00 L9.00 L1.57 L4.75 L3.43 L2.74 L14.87 L
Pretax Income 7.96 Cr3.03 Cr5.79 Cr5.30 Cr6.68 Cr5.10 Cr9.65 Cr8.90 Cr2.08 Cr11.77 Cr11.25 L1.75 Cr3.07 Cr
Tax Provision 3.31 Cr-0-079.02 L3.12 Cr-01.96 Cr-04.20 Cr00-15.59 L1.69 Cr
Net Income 4.65 Cr3.03 Cr5.79 Cr4.51 Cr3.55 Cr5.10 Cr7.69 Cr8.90 Cr-2.12 Cr11.77 Cr11.25 L1.90 Cr1.38 Cr
Diluted EPS 2.211.442.752.141.692.423.654.23-0.955.590.050.900.24

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 57.00 Cr53.00 Cr63.00 Cr62.00 Cr77.00 Cr85.00 Cr97.00 Cr-92.41 Cr107.92 Cr112.45 Cr105.81 Cr
Cost of Revenue --------61.50 Cr74.60 Cr76.47 Cr74.30 Cr
Gross Profit --------30.91 Cr33.31 Cr35.99 Cr31.51 Cr
Operating Expenses 54.00 Cr47.00 Cr56.00 Cr58.00 Cr76.00 Cr80.00 Cr90.00 Cr-23.57 Cr25.52 Cr33.44 Cr30.31 Cr
Operating Income -3.00 Cr6.00 Cr4.00 Cr1.00 Cr-2.00 Cr3.00 Cr7.00 Cr-7.34 Cr7.79 Cr2.55 Cr1.20 Cr
EBITDA 3.00 Cr7.00 Cr7.00 Cr4.00 Cr1.00 Cr6.00 Cr8.00 Cr-17.30 Cr22.96 Cr28.10 Cr19.05 Cr
Interest Expense 2.00 Cr1.00 Cr2.00 Cr1.00 Cr1.00 Cr00-8.25 L32.26 L23.18 L25.80 L
Pretax Income -3.00 Cr10.00 Cr6.00 Cr5.00 Cr3.00 Cr3.00 Cr11.00 Cr-15.89 Cr20.68 Cr25.67 Cr16.70 Cr
Tax Provision 1.44 Cr3.00 Cr3.30 Cr1.95 Cr1.89 Cr1.08 Cr3.63 Cr-3.31 Cr3.91 Cr6.16 Cr1.69 Cr
Net Income -1.00 Cr7.00 Cr3.00 Cr3.00 Cr1.00 Cr2.00 Cr7.00 Cr-12.58 Cr16.78 Cr19.50 Cr15.01 Cr
Diluted EPS -0.673.261.201.340.480.883.456.705.887.979.34-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 128.00 Cr144.00 Cr126.00 Cr122.00 Cr121.00 Cr121.00 Cr140.00 Cr-167.27 Cr182.37 Cr222.63 Cr242.14 Cr
Current Assets --------146.29 Cr160.98 Cr192.49 Cr210.90 Cr
Cash & Equivalents --------8.81 Cr1.71 Cr2.22 Cr63.72 L
Inventory --------12.64 Cr13.67 Cr17.64 Cr13.33 Cr
Receivables --------46.73 Cr41.15 Cr46.83 Cr40.83 Cr
Total Liabilities --------32.69 Cr30.46 Cr51.19 Cr55.86 Cr
Current Liabilities --------29.63 Cr28.07 Cr46.70 Cr52.53 Cr
Long Term Debt --------77.71 L000
Total Debt 29.00 Cr24.00 Cr11.00 Cr6.00 Cr2.00 Cr00-2.30 Cr5.25 Cr3.43 L2.51 Cr
Total Equity 87.00 Cr93.00 Cr95.00 Cr98.00 Cr98.00 Cr100.00 Cr108.00 Cr-134.58 Cr151.91 Cr171.43 Cr186.28 Cr
Shares Outstanding --------2.10 Cr2.10 Cr2.10 Cr2.10 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -2.00 Cr-22.00 Cr17.00 Cr-13.00 Cr-1.00 Cr18.00 Cr-2.00 Cr-8.90 Cr3.65 Cr7.06 Cr9.95 Cr
Investing Cash Flow 37.00 Cr-8.00 Cr-2.00 Cr-11.00 Cr-15.00 Cr-11.00 Cr6.00 Cr-2.13 Cr-13.34 Cr-1.10 Cr-11.56 Cr
Financing Cash Flow 7.00 Cr-6.00 Cr-15.00 Cr9.00 Cr-5.00 Cr-1.00 Cr0--3.79 Cr2.58 Cr-5.48 Cr2.22 Cr
Capital Expenditure -1.00 Cr-10.00 Cr-1.00 Cr-2.00 Cr-1.00 Cr-3.00 Cr-3.00 Cr--1.13 Cr-6.39 Cr-11.38 Cr-3.95 Cr
Free Cash Flow -3.00 Cr-32.00 Cr16.00 Cr-15.00 Cr-2.00 Cr15.00 Cr-5.00 Cr-7.78 Cr-2.74 Cr-4.32 Cr6.00 Cr
Net Change in Cash 42.00 Cr-36.00 Cr0-15.00 Cr-20.00 Cr5.00 Cr4.00 Cr-7.24 Cr-7.10 Cr47.78 L61.62 L

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------33.5%30.9%32.0%29.8%
Operating Margin % -5.3%11.3%6.3%1.6%-2.6%3.5%7.2%-7.9%7.2%2.3%1.1%
Net Margin % -1.8%13.2%4.8%4.8%1.3%2.4%7.2%-13.6%15.5%17.3%14.2%
ROE % -1.1%7.5%3.2%3.1%1.0%2.0%6.5%-9.3%11.0%11.4%8.1%
ROCE % --------5.3%5.1%1.5%0.6%

Shareholding Pattern

Insiders
57.29%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALPA

Google News Sun, 19 Apr 2026

Weighted Alpha: Meaning, Calculation, Inferences - Investopedia

<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE1qLU9sSDEzbWVLdXRFTTRGODM1Rm8zbFF0Zk56NDB3aGxVX2M3R2ZXcTNDeTByM0dnNnNJaUZ2cG4yb0I4enotU01rZ0QwVkdvWkp4MGJDaEVlb0F1NXRkRTJBUmM?oc=5" target="_blank">Weighted Alpha: Meaning, Calcula…

Google News hu, 10 Sep 2026

Alpha Metallurgical Resources Director Courtis Buys $2.3 Million Shares. Is it Time for You to Buy Too? - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPQlBhVk10UnVtaDZJWXJaWDYtZXpqOWp3ZFB0S3ZmYUxsTEpUcjdhVlIyRGpYRXY2VzB5OXVzNl92WHhUYUM1S1pQVmM1Z01MTjdCWHg1YlBsTWNuamdzaDRrQTQ0dGtJckJianotLXpZcFN2SXNiNXZ5QWdTTDhMYjJnQk9XYmdNNVNFLX…

Google News Sat, 22 Aug 2026

Alpha Metallurgical Resources Director Courtis Buys $2.9 Million Shares. What Does This Mean for Investors? - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPVDJfQThmdmJjRnNrak9sekV0WWVHVndGZXhXdXBGYlJ3TUdvT0hCR2JmOFd5VF9ELTJIcG8wd0JxWGpqN1djUUtDdEFtSXFSN0ZHU1lIdTE2ZEpqVjlCUmc0anlQUWJxcTRtbGFveV9fUjFwQl9nWVhJZmtzZ2RSVU0zVnJiV0huYWVLZm…

Google News Mon, 26 Jun 2017

Alpa Laboratories Limited (ALPA.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE4zcVB2eUVBYU43RVRVVlhEc280SXd0UXk5VG1FSHZNWUY4RjQwWTJRaVY1RlFPV2JQUmtaU0E1VDhZamp1UmVtTjd1NTN4OWl0aDhxQzRB?oc=5" target="_blank">Alpa Laboratories Limited (ALPA.NS) Stock Price, Ne…

Google News Fri, 01 Jul 2022

Alpha Picks by Seeking Alpha, Choose 2 Stocks Per Month - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5HZ0x6STEzOHd5LUNfdWV6MUNSNjNwcjN1WjhlUnc4QWJ1SEk5OFFCMkhlNUp1bU1TRW5sSG1qeXRNN21VTFlqZjktSVBKaDZiOUV0Z0x2M3BmUQ?oc=5" target="_blank">Alpha Picks by Seeking Alpha, Choose 2 Stocks…

Google News Fri, 05 Feb 2021

AMR Stock Price and Chart — NYSE:AMR - TradingView

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE41azdQYzZqeEtXMnB2bHMwa1dTS0tSb1ZGWEVhTG5KeVV1djRyRW5pWmlNZGxCQWFhVV9FR21LV2NwanVra282TWpaWHRoUERJTkFlbGZWbTE?oc=5" target="_blank">AMR Stock Price and Chart — NYSE:AMR</a>&nbsp;&n…

ALPA — Frequently Asked Questions

What is the current share price of Alpa Laboratories Limited (ALPA)?

As of 2026-10-24 04:55 IST, Alpa Laboratories Limited (ALPA) trades at ₹51.46 on NSE. Its 52-week range is ₹46.46 to ₹99.47.

What is the market capitalisation of ALPA?

Alpa Laboratories Limited (ALPA) has a market capitalisation of ₹108.27 Cr on NSE.

What is the P/E ratio of ALPA?

ALPA trades at a trailing price-to-earnings (P/E) ratio of 30.63. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 0.64.

What is the return on equity (ROE) of ALPA?

ALPA has a return on equity (ROE) of 8.06%. Its return on capital employed (ROCE) is 8.94%.

Is ALPA a good stock to buy?

This page provides a data-driven analysis of Alpa Laboratories Limited (ALPA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space